ArticleClinical and translational science2023

First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia.

Michael Boyiadzis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.